Neurologic Aspects of Inflammatory Bowel Disease
Neurol 45:416-421, Lossos,A.,et al, 1995
Clinical Pathological Conference
Giant-cell Arteritis of Temporal Artery (temporal arteritis) , Case Record 35-1977, NEJM 297:4927., , 1977
Neurological Problems in Endocrine Diseases
Med Clin North Am 56:1029, Dale,A., 1972
Neurologic Manifestations of SLE 1972
Nebraska State Journ Med, Oct 1972, pp 395., Aita,J., 1972
Mechanisms, Causes, and Effects of Hypercapnia
UptoDate Dec, Feller-Kopman, D.J. & Schwartzstein, R.M., 2016
Juvenile Myasthenia Gravis: Recommendations for Diagnostic Approaches and Treatment
Neuropediatrics 45:75-83, Marina, A.D.,et al, 2014
Multifocal Paraneoplastic Cortical Encephalitis Associated With Myasthenia Gravis and Thymoma
Arch Neurol 66:1407-1409, Hammoud,K.,et al, 2009
Concomitant Chronic Inflammatory Demyelinating Polyneuropathy and Myasthenia Gravis Following Cytomegalovirus Infection
J Neurol Sci 240:103-106, Mori, M.,et al, 2006
Does This Patient Have Myasthenia Gravis?
JAMA 293:1906-1914, Scherer,K.,et al, 2005
Middle Ear Effusions and Myasthenic Gravis
J Laryn and Otology, 102:169-1701988., O'Reilly,B.J., 1988
Myasthenia Gravis Assoc. with Wasp Sting
JAMA 235:2120, Brumlik,J., 1976
Acute Bulbar Dysfunction & Hyperthyroidism
Am J Med 56:464, Kammer,G.M.,et al, 1974
Multiple Sclerosis Associated with Defects in Neuromuscular Transmission
JNNP 35:385, Patten,B.M.,et al, 1972
A 71-Year-Old Man Presenting with Acute Onset Dysarthria and Dysphagia
Neurol 96:180-184, Spagni, G.,et al, 2021
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018
Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018
Clinical Manifestations of Myasthenia Gravis
UptoDate Aug 2016, Bird, S.J., 2016
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016
Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014
Overlooked non-motor Symptoms in Myasthenia Gravis
JNNP 84:989-994, Suzuki, S.,et al, 2013
Clinicopathologic Conference, Inflammatory Myopathy and Myasthenia Gravis Assoc. with Thymoma
NEJM 369:764-773, Case 26-2013, 2013
Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Evidence-Based Guideline Update: Plasmapheresis in Neurologic Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 76:294-300, Cortese,I.,et al, 2011
Clinicopathologic Conference, Thymoma with Paraneoplastic Myasthenia Gravis, Polymyositis and Myocarditis, and Brain Stem Encephalitis
NEJM 365:2413-2422, Case 39-2011, 2011
Bilateral Ocular Paralysis: Analysis of 31 Inpatients
Arch Neurol 64:178-180, Keane,J.R., 2007
Mysterious Falls and a Nasal Voice
Lancet 370:712, Bhandari,A. &Adenwalla,F., 2007
Plasma Exchange in Neuroimmunological Disorders: Part 2. Treatment of Neuromuscular Disorders
Arch Neurol 63:1066-1071, Lehmann,H.C.,et al, 2006
Dysphagia as the Sole Manisfestation of Myasthenia Gravis
JNNP 76:1297-1300, Llabrs,M.,et al, 2005
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Difference in Distribution of Muscle Weakness Between Myasthenia Gravis and the Lambert-Eaton Myasthenic Syndrome
JNNP 73:766-768, Wirtz,P.W.,et al, 2002
Thymoma in Patients with MG
Neurol 59:1844-1850, Evoli,A.,et al, 2002
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Intravenous Immunoglobulin in the Treatment of Autoimmune Neuromuscular Diseases:Present Status and Practical Therapeutic Guidelines
Muscle & Nerve 22:1479-1497, Dalakas,M.C., 1999
Respiratory Management in Acute Neurologic Illness
Neurol 50:11-20, Wijdicks,E.F.M.&Borel,C.O., 1998
Morvan's Fibrillary Chorea: A Paraneoplastic Manifestation of Thymoma
JNNP 65:857-862, Lee,E.K.,et al, 1998
Myasthenia Gravis and Alopecia Areata
Neurol 48:774-775, Kubota,A.K.,et al, 1997
Bent Spine Syndrome
JNNP 60:51-54, Serratrice,G.,et al, 1996
Intravenous Immunoglobulin Treatment of Neurological Disease
JNNP 60:359-361, Otten,A.,et al, 1996
Intestinal Pseudo-Obstruction, Myasthenia Gravis, and Thymoma
Neurol 47:985-987, Anderson,N.E.,et al, 1996
Assoc of Myasthenia Gravis with Extrathymic Hodgkin's Lymphoma:Resol of Myasth Sympt Following Antineopl Therapy
Neurol 45:1019, Abrey,L.E.&Askanas,V., 1995
Plasma Exchange and Intravenous Immunoglobulin Treatment of Neuromuscular Disease
Ann Neurol 35:260-268, Thornton,C.A.&Griggs,R.C., 1994
Myasthenia Gravis
NEJM 330:1797-1810, Drachman,D.B., 1994
Acute Neuromuscular Respiratory Paralysis
JNNP 56:334-343, Hughes,R.A.C.&Bihari,D., 1993
Differential Diagnosis of Guillain-Barre Synd, In Guillain-Barre Synd
Thieme Med Publ, Ch 3, p 42993., Parry,G.J., 1993